Genome & Company Reports Conversion of 2.52 Million Preferred Shares into Common Shares, Diluting Existing Shareholders by 5.2%
On July 14, 2026, Genome & Company received a conversion request for 2,520,706 convertible preferred shares into common shares at a 1:1 ratio.
The total common shares outstanding will increase from 48,354,309 to 50,875,015, a 5.21% dilution of existing shareholders' equity.
The new shares are scheduled to be listed on August 10, 2026, subject to change upon consultation with relevant authorities.
[AI Summary]The conversion of preferred shares into common shares results in approximately 5.2% equity dilution, but this is a planned capital structure change with no new capital inflow. While it may pressure the stock price short-term, no change in management control or new fundraising purpose is identified.
KOSDAQ Filing Information
Other Management Matters (Voluntary Disclosure) (Conversion Request of Convertible Preferred Shares into Common Shares)